The company was jointly founded by two graduates from Peking University School of Pharmacy, and is a high-tech enterprise that integrates academic wisdom and industry experience. The core team of the company is composed of senior drug development experts who have accumulated decades of rich experience in the field of drug development and are committed to transforming academic research results into medical products with practical application value. The establishment and development of the company are attributed to this outstanding team.
Xiaobao.Chen
Chen Xiaobao, the founder and general manager of Scindy Biotechnology, has not only been awarded the honorary titles of Suzhou Gusu Innovation and Entrepreneurship Leading Talent and Suzhou Industrial Park Innovation and Entrepreneurship Leading Talent for his outstanding contributions in innovation and entrepreneurship, but also demonstrated outstanding leadership in promoting the reform and innovative development of the pharmaceutical industry. I have served as a research and development leader in several well-known pharmaceutical companies such as Concord Pharmaceutical, Neovia, and Dongyao Pharmaceutical (1875. HK), leading over 10 drug development projects, especially in the field of lipid nanoparticle drugs. With profound professional knowledge and practical experience, I have contributed valuable wisdom and strength to the industry and successfully promoted the first MAH pilot project in Jiangsu Province.
Dr. Wang Wei
Wang Wei, as the chief scientist of the company, is also a professor and doctoral supervisor at the University of Bergen Pharmacy Center. Dr. Wang's research areas are extensive, including lipid and polymer synthesis, self-assembly of soft materials, and their applications in drug delivery. His research results have been published in over 100 internationally renowned journals such as Nature Communications, providing a solid theoretical foundation for the company's technological innovation.
Core Technology
Full Chain LNP Delivery Technology Solution (TLS)
With its profound accumulation in the field of nanocarrier technology, the company has successfully developed a full chain LNP delivery technology solution (TLS) and constructed a core lipid material library and RNA sequence design model. The i-Core LNPTM platform technology developed by the company is particularly suitable for extrahepatic targeted RNA delivery through lung nebulization inhalation and local skin administration, opening up new avenues for the clinical application of synthetic biology and RNA therapy. In addition, the NeoLNPTM series products launched by the company provide efficient solutions for transfection in cells and animals.
|
NeoLNP?: Cell and animal |
| RNA transfection lipid nanoparticle kit |
NeoLNP? RNA transfection kit (In Vitro/In Vivo) is based on independently developed advanced European LNP core technology, designed specifically for laboratory applications, providing efficient RNA-LNP encapsulation solutions. No specialized equipment is required, the entire packaging process can be completed in just 1 minute. This technology achieves efficient delivery of RNA through the unique transmembrane transport and endosome escape mechanisms of LNP, meeting the diverse needs of cell and animal RNA transfection and unleashing the potential of RNA gene regulation. NeoLNP ? RNA The transfection kit is suitable for encapsulation and delivery of various RNA types such as mRNA, sgRNA, saRNA, circRNA, etc., providing a one-stop delivery solution for RNA therapies such as gene editing and cell therapy.
|
NeoLNP?: 1-minute efficient RNA |
| encapsulation solution |
|
NeoLNP?: The LNP Kit for RNA transfection |
| from cells to animals (In Vitro/In Vivo) |
|
NeoLNP?: Diversified application scenarios |
|
i-Core LNPTM: Innovative RNA |
| multiplex delivery solution |
This platform is an LNP (Lipid Nanoparticle) formulation design system developed by the company based on the QbD (Quality by Design) concept. The platform customizes targeted delivery LNP solutions based on different administration routes and treatment mechanisms, providing stable and reliable RNA delivery efficiency with extremely high safety, which is crucial for the success of RNA therapy. This innovative breakthrough will help further expand the application scope of RNA therapy.
Pulmonary administration of RNA-LNP delivery protocol
The lung administration LNP regimen developed by the company effectively overcomes the stability issues during inhalation/nebulization, and has excellent tissue targeting properties, achieving efficient expression of RNA in lung tissue without off target phenomena. This approach provides an innovative solution for RNA drug delivery in lung diseases and has become a key carrier for cutting-edge RNA therapies such as gene editing and protein replacement.
Skin targeted LNP regimen
The company has designed and developed an efficient and safe LNP delivery system specifically for topical skin administration, such as peptides, small nucleic acids, mRNA, etc. This scheme can achieve skin targeted delivery of RNA with low immune irritation, demonstrating the clinical potential of the new generation of RNA therapy in protein replacement and anti-aging treatment.
疫LNP delivery scheme for vaccines using independent IP
Based on its independently developed lipid material library and formula development system, the company has successfully developed an LNP delivery solution suitable for mRNA vaccines, which can efficiently deliver to immune system sites such as lymph nodes and spleen. Its performance and safety have reached the level of international similar LNP products on the market.
With the continuous innovation and breakthroughs of the company in the field of nanocarrier technology, its advanced RNA delivery technology not only opens up new avenues for the clinical application of synthetic biology and RNA therapy, but also brings revolutionary changes to the entire pharmaceutical industry. With its strong research and development capabilities and excellent team, the company is continuously promoting RNA therapy from the laboratory to clinical practice, from theory to practice, bringing safer and more effective treatment options to patients. Looking ahead to the future, Scindy Biotechnology will continue to work with global partners to explore the infinite possibilities of RNA therapy and contribute to the cause of human health.
